Biocon Publishes Yesafili Clinical Trial Data

Peer-reviewed Phase III studies reinforce the safety and efficacy of Yesafili, a biosimilar to Eylea® (aflibercept)

Biocon has announced the publication of two peer-reviewed clinical studies supporting the effectiveness of Yesafili™ (aflibercept-jbvf), its biosimilar to Eylea®. The publications are based on data from the Phase III INSIGHT clinical program and demonstrate that Yesafili offers comparable safety, efficacy and immunogenicity to the reference product in patients with diabetic macular oedema (DMO). The findings strengthen the clinical evidence supporting the product ahead of its planned commercial expansion.

Strong Clinical Evidence from Phase III Trials

The published studies evaluated patients who either continued treatment with Yesafili or switched from the reference aflibercept therapy. Results showed no clinically meaningful differences between the treatment groups in visual acuity improvement, retinal thickness reduction or safety outcomes. The data also confirmed consistent immunogenicity profiles, reinforcing the biosimilar's clinical comparability.

Supporting Greater Access to Retinal Therapies

The clinical publications highlight Biocon's commitment to expanding access to high-quality biosimilars for retinal diseases. By generating robust clinical evidence through the INSIGHT program, the company aims to provide healthcare professionals with greater confidence in adopting biosimilar therapies while improving treatment accessibility for patients requiring long-term anti-VEGF therapy.

Advancing Biosimilar Innovation

The publication of these studies represents another milestone in Biocon's biosimilars portfolio. The peer-reviewed data support the scientific foundation of Yesafili and reinforce its role as a reliable treatment option for retinal disorders, contributing to the broader adoption of affordable biologic therapies worldwide.

Key Features

1. Phase III INSIGHT clinical data published in peer-reviewed journals
2. Demonstrated comparable safety, efficacy and immunogenicity to Eylea®
3. Supports the use of Yesafili in diabetic macular oedema treatment
4. Strengthens clinical evidence ahead of broader commercialization
5. Reinforces confidence in biosimilar adoption among healthcare providers

Applications

1. Diabetic macular oedema (DMO) treatment
2. Retinal disease management
3. Ophthalmology clinical practice
4. Biosimilar-based anti-VEGF therapy
5. Vision care and retinal healthcare programs

Strengthening Confidence in Biosimilars

The publication of the INSIGHT clinical data further validates Yesafili as an effective biosimilar to Eylea®, supporting its use in retinal disease treatment. By providing strong scientific evidence through peer-reviewed research, Biocon continues to advance affordable biologic therapies and improve access to vision-saving treatments for patients worldwide.